CLIA Categorization Duties Transfer To FDA From CDC Under Negotiation
This article was originally published in The Gray Sheet
Executive SummaryDiscussions are under way between FDA and the Centers for Disease Control and Prevention that could result in FDA recouping responsibility from CDC for categorization of in vitro diagnostics under the Clinical Laboratory Improvement Amendments of 1988, the Health Industry Manufacturers Association reports.
You may also be interested in...
ConMed's CFO Todd Garner told delegates at the Jefferies Healthcare conference that the company's orthopedic franchise is focused on its pipeline and meeting customer's needs. See what the CFO said about it here.
Formal dispute resolution was key element in four-month turnaround from rejection by US FDA to approval for golodirsen, the second Sarepta DMD drug to clear the agency after appearing to have minimal prospects.
Correvio’s attempt to move vernakalant from 'clinical hold' to 'FDA approved' was a huge long shot. But the advisory committee vote – and looming FDA rejection – are another indication that real-world data is not a panacea.